GSK: Blenrep Approved by U.S. FDA for Use in Treatment of Relapsed/refractory Multiple Myeloma
October 24, 2025
October 24, 2025
LONDON, England, Oct. 24 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Oct. 23, 2025:
* * *
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
* Significant unmet need for patients requires new and novel treatments/1
* DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a da . . .
* * *
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
* Significant unmet need for patients requires new and novel treatments/1
* DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a da . . .